Macrogenics (FRA:M55) Total Assets : €249.9 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Total Assets?

Macrogenics's Total Assets for the quarter that ended in Dec. 2024 was €249.9 Mil.

During the past 12 months, Macrogenics's average Total Assets Growth Rate was -12.60% per year. During the past 3 years, the average Total Assets Growth Rate was -13.20% per year. During the past 5 years, the average Total Assets Growth Rate was -9.20% per year. During the past 10 years, the average Total Assets Growth Rate was 15.60% per year.

During the past 13 years, Macrogenics's highest 3-Year average Total Assets Growth Rate was 70.00%. The lowest was -13.60%. And the median was 29.70%.

Total Assets is connected with ROA %. Macrogenics's annualized ROA % for the quarter that ended in Dec. 2024 was -24.13%. Total Assets is also linked to Revenue through Asset Turnover. Macrogenics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.07.

Macrogenics Total Assets Historical Data

The historical data trend for Macrogenics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Total Assets Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

311.33

296.69

264.76

273.65

249.88

Macrogenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															273.65	228.42	186.86	238.31	249.88

Macrogenics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Macrogenics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	110.834	+	139.046
	=	249.9

Macrogenics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	110.834	+	139.046
	=	249.9

Macrogenics (FRA:M55) Total Assets Explanation

Total Assets is connected with ROA %.

Macrogenics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-58.908	/	( (238.307	+	249.881)	/ 2 )
	=	-58.908	/	244.094
	=	-24.13 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Macrogenics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	16.932	/	( (238.307	+	249.881)	/ 2 )
=	16.932	/	244.094
=	0.07

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Macrogenics Total Assets Related Terms

Thank you for viewing the detailed overview of Macrogenics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics Headlines

No Headlines